Ameer Khan
Critical Care Medicine · Elizabeth City, NCNPI 1902118458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $918 and has fallen 94.6% since, to $50 in 2025.
Across 91 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$256
- Boehringer Ingelheim$222
- Actelion Pharmaceuticals US, Inc.$177
- Amgen$130
- AstraZeneca$110
- ANI Pharmaceuticals, Inc.$94
- plus $862 from 27 others
What the payments were for
- Food & beverage$1,77896%
- Education$724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $256 |
| Boehringer Ingelheim | 9 | $222 |
| Actelion Pharmaceuticals US, Inc. | 7 | $177 |
| Amgen | 3 | $130 |
| AstraZeneca | 7 | $110 |
| ANI Pharmaceuticals, Inc. | 4 | $94 |
| Sanofi | 3 | $84 |
| Genentech USA, Inc. | 5 | $75 |
| Novartis | 2 | $63 |
| United Therapeutics Corporation | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Baxter Healthcare | 2 | $34 |
| Mylan Specialty L.p. | 2 | $33 |
| Pharming Healthcare, Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Stryker | 1 | $27 |
| Inogen, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Pulmonx Corporation | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| AbbVie | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| Pfizer | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $11 |
How this compares
$1,851 in reported general payments places this provider in the 75th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,172 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $256 | $25,17227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Elizabeth City
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
- Andrea MacdonaldRaleigh$67K
- John DotyCharlotte$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.